HARMONY BIOSCIENCES HLDG INC (HRMY) competitors & alternatives
Health Care · NASDAQ
HARMONY BIOSCIENCES HLDG INC (HRMY)'s top competitors and alternatives — its most similar public companies — include Jazz Pharmaceuticals (JAZZ), BIOHAVEN LTD (BHVN), Neurocrine Biosciences (NBIX), Insmed (INSM), SIONNA THERAPEUTICS INC (SION), NURIX THERAPEUTICS INC (NRIX), KURA ONCOLOGY INC (KURA), SOLID BIOSCIENCES INC (SLDB), RELMADA THERAPEUTICS INC (RLMD), PROTHENA PLC (PRTA), AGENUS INC (AGEN) and VOYAGER THERAPEUTICS INC (VYGR). These are HARMONY BIOSCIENCES HLDG INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top HRMY competitors & alternatives
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
BIOHAVEN LTDBHVNHealth Care
Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using…
$14.75 (as of 2026-07-22) · market cap $2.3B
-
Neurocrine BiosciencesNBIXHealth Care
Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric…
$172.69 (as of 2026-07-22) · market cap $17.8B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
SIONNA THERAPEUTICS INCSIONHealth Care
A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
$45.03 (as of 2026-07-22) · market cap $2.1B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
RELMADA THERAPEUTICS INCRLMDHealth Care
Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead…
$5.00 (as of 2026-07-22) · market cap $524M
-
PROTHENA PLCPRTAHealth Care
A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through…
$8.44 (as of 2026-07-22) · market cap $458M
-
AGENUS INCAGENHealth Care
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term…
$5.53 (as of 2026-07-22) · market cap $232M
-
VOYAGER THERAPEUTICS INCVYGRHealth Care
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while…
$3.10 (as of 2026-07-22) · market cap $187M
Not quite? Describe exactly what you want →
Peers are HARMONY BIOSCIENCES HLDG INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: HARMONY BIOSCIENCES HLDG INC (HRMY).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.